Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.
Hemogenyx Pharmaceuticals has raised £620,000 through convertible loan notes to support the clinical trial of its CAR-T cell therapy, HG-CT-1, targeting relapsed or refractory acute myeloid leukemia. This funding, backed by a small investor group, reflects confidence in the company’s strategy and will bolster its financial position, allowing it to continue advancing its clinical development efforts.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 65,181
Technical Sentiment Signal: Buy
Current Market Cap: £25.05M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.